Liver Fluke Treatment Market Size & Share 2026-2035

Liver Fluke Treatment Market Size

The global liver fluke treatment market was valued at USD 642.7 million in 2025. The market is expected to grow from USD 668 million in 2026 to USD 1 billion in 2035, growing at a CAGR of 5% during the forecast period, according to the latest report published by Global Market Insights Inc.

Furthermore, the market is bolstered by technological advancements in diagnostic methods, such as PCR-based testing, which has improved early detection rates of liver fluke infections driving market demand. Moreover, the market growth is driven by the growing trend of preventive measures in endemic regions with increasing investments in healthcare infrastructure and pharmaceutical R&D activities supporting the development of new drugs and treatment protocols for liver fluke infections.

Liver fluke treatment refers to the medical and veterinary interventions aimed at diagnosing, managing, and curing infections caused by parasitic flatworms known as liver flukes. These parasites infect the liver, bile ducts, and gallbladders of humans and animals, leading to a range of health complications. The treatment involves the use of antiparasitic drugs, supportive therapies, and preventive measures to eliminate the parasites and manage associated symptoms, or complications. Key players operating in this market include Novartis, Merck, Zoetis, Bayer, and Virbac. These companies are actively shaping the liver fluke treatment market through extensive product portfolios, global distribution networks, and targeted R&D.

Between 2022 and 2024, the liver fluke treatment market witnessed growth from USD 575 million in 2022 to USD 618.8 million in 2024. The increasing awareness of liver fluke–related health risks and government-led screening programs in endemic regions boosted adoption of antiparasitic treatments during this period. Additionally, the rising livestock production, preventive deworming initiatives, and the economic impact of fluke infections on animal health have also driven the widespread use of flukicides.

Liver Fluke Treatment Market Trends

• The liver fluke treatment market is witnessing steady growth driven by a combination of economic, epidemiological, and technological factors. Liver fluke infections impose a substantial economic burden on the livestock sector, with global losses exceeding USD 3 billion annually due to reduced productivity, poor weight gain, and lower milk yield. This has encouraged farmers and veterinary professionals to increasingly adopt flukicide treatments and preventive healthcare practices, thereby supporting market expansion.
• At the same time, the inclusion of key drugs such as triclabendazole in the World Health Organization’s Essential Medicines List has significantly improved access to treatment in endemic regions through subsidized distribution programs, further boosting market demand.
• In addition, the rising prevalence of liver fluke infections, particularly in developing regions across Asia and Africa, continues to drive the need for effective treatment solutions. Factors such as poor sanitation, consumption of contaminated food, and increased livestock exposure contribute to sustained transmission rates.
• Climate change is also playing a critical role by expanding the habitat of intermediate snail hosts, leading to the spread of infections into new geographic areas and creating additional demand for both human and veterinary therapeutics.
• Furthermore, growing awareness regarding animal healthcare and the economic impact of parasitic infections has led to increased adoption of routine deworming practices and government-supported livestock health initiatives.

Liver Fluke Treatment Market Analysis

Based on drug type, the global liver fluke treatment market is divided into triclabendazole, praziquantel, bithionol, albendazole, nitazoxanide, and other drug types. The triclabendazole segment dominated the market and was valued at USD 266.4 million in 2025.

• The increasing cases of liver fluke infections, especially in countries where the disease is endemic such as parts of Southeast Asia, South America, and sub-Saharan Africa, drive the demand for effective treatments like triclabendazole, thereby contributing to market growth.
• Moreover, the high efficacy and safety of triclabendazole for the treatment of liver fluke infections, particularly fasciola hepatica, have contributed to its continued use for liver fluke infections, especially in human and veterinary applications.
• Furthermore, triclabendazole is relatively affordable compared to some other anti-parasitic drugs, making it an attractive option in low- and middle-income countries where liver fluke infections are prevalent. Cost-effectiveness is a major factor that influences the accessibility of the drug in rural and underserved areas.
• On the other hand, the bithionol segment is expected to grow at 5.5% over the analysis period, primarily due to its role as an alternative treatment option in cases where first-line therapies such as triclabendazole are ineffective or contraindicated.
• The increasing emergence of drug resistance to triclabendazole in certain endemic regions has renewed interest in bithionol as a second-line therapy, supporting its demand. Additionally, bithionol is particularly useful in treating patients who exhibit intolerance or limited response to standard treatments, making it an important component in diversified treatment protocols.

Based on the formulation type, the global liver fluke treatment market is categorized into tablets, injections, and oral suspension. The tablets segment accounted for the highest market share of 41.4% in 2025.

• Tablets have a longer shelf life and require less stringent storage conditions compared to liquid formulations or biologics. This is particularly important for distribution to remote areas where refrigeration may not be available.
• Moreover, with advancements in pharmaceutical technology, tablets now offer better bioavailability and controlled release properties. Modern tablet formulations formulated with sustained-release excipients can improve therapeutic outcomes and reduce the frequency of dosage.
• Furthermore, tablets for treating liver fluke infections have been well-established in many regions, with clear guidelines for approval by regulatory bodies like the FDA, EMA, and WHO. This facilitates the availability and accessibility of these formulations in global markets, thereby spurring market growth.
• On the other hand, the oral suspension segment is predicted to grow significantly at 5.3% CAGR over the analysis period, primarily driven by its ease of administration and improved patient compliance, particularly among pediatric and geriatric populations who may have difficulty swallowing tablets.
• Oral suspensions offer flexible dosing and better palatability, making them a preferred option in mass drug administration programs and in regions with high disease burden.

Based on the application, the global liver fluke treatment market is categorized into human and animals. The human segment accounted for the highest market share in 2025 and is expected to grow at a CAGR of 4.8% during the analysis period.

• The rising awareness regarding the severity of liver fluke infections, including conditions such as liver cirrhosis, bile duct cancer, and other hepatobiliary diseases, has significantly contributed to the growth of the human application segment.
• Liver fluke infections often have a veterinary dimension, especially in livestock. Infected animals, particularly cattle and sheep, are a major source of infection in human. As awareness grows about the link between veterinary and human infections, the demand for treatment is expanding, not just for animal treatments, but also to prevent zoonotic transmission to human, which further supports market growth.
• On the other hand, the animal segment is predicted to grow at 5.2% CAGR over the forecast period, primarily driven by the increasing economic impact of liver fluke infections on livestock productivity.
• Farmers are becoming more aware of the losses associated with reduced milk yield, poor weight gain, and liver condemnation, which is encouraging the adoption of routine deworming and preventive treatment practices.

Based on the end use, the global liver fluke treatment market is categorized into hospitals, specialty clinics, and other end users. The hospitals segment dominated the market in 2025 and is anticipated to reach USD 428.7 million by 2035.

• Hospitals are equipped with advanced diagnostic tools and treatment facilities, making them central to managing complex cases of liver fluke infections. Their capacity to provide comprehensive care, including surgical interventions, when necessary, enhances patient outcomes and drives the demand for specialized treatments, thereby contributing to market growth.
• Additionally, hospitals often offer supportive therapies, such as palliative care and nutritional support, which play a vital role in improving the overall health condition of affected individuals and enhancing recovery outcomes post-treatment.
• Moreover, hospitals adhere to established treatment protocols and benefit from the availability of FDA-approved medications, such as triclabendazole, which is considered first-line therapy for liver fluke infections. The approval and availability of such drugs in hospital settings ensure standardized and effective treatment regimens.

North America Liver Fluke Treatment Market

North America liver fluke treatment market was valued at USD 261.8 million in 2025.

• The growth is primarily driven by its advanced healthcare and veterinary infrastructure, which supports widespread diagnosis and treatment, along with a strong livestock industry that drives demand for parasite control to prevent productivity losses in cattle and dairy farming.
• The region also benefits from the availability of effective anthelmintic drugs, continuous research and development by major pharmaceutical companies, and high awareness among farmers and healthcare professionals leading to routine preventive treatments, thereby contributing to the market’s growth.

In 2025, the U.S. held a significant position in the North America liver fluke treatment market and was valued at USD 232.9 million.

• Innovations in anthelmintic medications, such as triclabendazole, have enhanced treatment efficacy. Triclabendazole is recognized as a first-line therapy for liver fluke infections by the CDC and WHO. Its effectiveness in treating chronic fascioliasis has bolstered its adoption in veterinary practices, contributing to market expansion, thereby boosting the market growth.
• Moreover, regulatory approvals for new treatments have facilitated market growth. For instance, Novartis received U.S. FDA approval for its liver fluke treatment drug, Egaten (triclabendazole), for patients aged six years and older. Such approvals enhance treatment accessibility and spur market growth.

Europe Liver Fluke Treatment Market

Europe liver fluke treatment market was valued at USD 149.3 million in 2025 and is expected to reach USD 244.5 million by 2035.

• The region has seen a rise in liver fluke infections linked to climate change, with wetter conditions increasing parasite transmission, especially in livestock across Mediterranean and Western Europe.
• Europe’s large and highly regulated cattle and sheep farming sector drives consistent demand for flukicides to prevent significant economic losses in meat and dairy production.
• Additionally, strict food safety and animal welfare regulations require routine parasite control, further supporting market growth.
• Moreover, ongoing R&D, improved drug formulations, and growing awareness of zoonotic risks are expected to sustain steady market expansion through 2035.

Germany shows strong growth potential in the liver fluke treatment market.

• German regulatory bodies and veterinary associations are actively promoting the control and treatment of liver fluke infections. This includes implementing surveillance programs, providing guidelines for treatment protocols, and supporting research into new therapeutic options.
• Thus, such initiatives ensure the availability and accessibility of effective treatments, fostering market growth.
• Moreover, Germany has seen a rise in the number of diagnosed cases due to better screening methods. Studies indicate that more healthcare facilities are now adopting diagnostic tools such as ultrasound and serology tests to detect liver fluke infections early, which has contributed to the demand for liver fluke treatments in Germany.
• Additionally, the German government and health authorities have been active in tackling parasitic diseases through public health campaigns and by funding research into the development of more effective treatment.

Asia Pacific Liver Fluke Treatment Market

The liver fluke treatment market in Asia Pacific is estimated to grow at a CAGR of 5.3% over the next few years.

• Liver fluke infections, caused by parasitic worms, are endemic in parts of China, particularly in rural and agricultural areas. The consumption of raw or undercooked freshwater fish, a common dietary habit, contributes to the transmission of liver flukes.
• Moreover, the Chinese government has been taking active measures to control parasitic diseases, including liver fluke infections. Programs that focus on public health education, improving sanitation, and controlling food safety contribute to raising awareness and increasing demand for treatment options.
• Furthermore, China’s growing international trade and tourism have also contributed to an increase in the spread of liver fluke infections. As people travel to and from endemic areas, the incidence of liver fluke infections could increase, necessitating better treatment and awareness, thereby strengthening market presence.

Latin America Liver Fluke Treatment Market

Brazil's liver fluke treatment market is projected to witness growth in the coming years.

• Brazil is one of the world's largest producers of beef and dairy products. The economic importance of livestock necessitates stringent measures to prevent liver fluke infestations that could cause significant financial losses.
• Furthermore, the availability of proven therapies, such as triclabendazole, for the treatment of liver fluke infections has positively influenced the market. The World Health Organization's endorsement of triclabendazole for fascioliasis has driven its adoption in Brazil.

Middle East and Africa Liver Fluke Treatment Market

Saudi Arabia is anticipated to grow in the Middle East and African liver fluke treatment market.

• The Saudi government has been enhancing veterinary services to ensure livestock health. Increased funding for veterinary healthcare allows for better access to liver fluke treatments.
• Moreover, Saudi Arabia is collaborating with international veterinary and pharmaceutical firms to develop and import innovative liver fluke treatments, thereby fostering market growth.
• Furthermore, Saudi Arabia's Ministry of Health has strengthened its focus on combating infectious diseases, including parasitic infections. This has led to better diagnosis, treatment protocols, and public health awareness campaigns targeting rural areas where the risk of liver fluke infections is higher, thereby contributing to the market growth.

Liver Fluke Treatment Market Share

The liver fluke treatment market share is shaped by the strong presence of established pharmaceutical and animal health companies alongside emerging biotech firms, creating a highly competitive landscape. Key players such as Novartis, Merck, Zoetis, Bayer, and Virbac accounted for a significant market share of 58.9% due to their extensive product portfolios, global distribution networks, and continuous investments in research and development. These companies maintain their market share by introducing advanced formulations, improving drug efficacy, and ensuring wider accessibility.

At the same time, emerging biotech firms are gradually capturing smaller but growing shares by focusing on innovative therapies and novel mechanisms of action. Competitive dynamics are further influenced by pricing strategies, strategic partnerships, mergers, and acquisitions, which help companies expand their geographic presence and strengthen their pipelines. Additionally, collaborations with research institutions and a focus on affordability and sustainable solutions are enabling both established and new entrants to increase penetration in underserved regions, collectively shaping a dynamic and evolving market share distribution.

Liver Fluke Treatment Market Companies

Prominent players operating in the liver fluke treatment industry are mentioned below:

• AdvaCare Pharma
• Bayer Healthcare
• GlaxoSmithKline
• Lupin Pharma
• Merck
• Novartis
• Par Pharmaceutical
• Pfizer
• Schering Corporation
• Vetoquinol
• Virbac
• Zoetis 

Novartis

Novartis is a leading player in the liver fluke treatment market, contributing a notable share of 20.4% through its strong pharmaceutical expertise and established antiparasitic drug portfolio. The company leverages its extensive R&D capabilities and global distribution network to develop and supply effective treatments, while its focus on innovation and strategic partnerships helps maintain its competitive position in both human and veterinary segments.

Merck

Merck holds a significant position in the liver fluke treatment market, supported by its strong animal health division and wide range of parasiticides. The company benefits from robust research capabilities, advanced product formulations, and a well-established global presence, enabling it to effectively address liver fluke infections in livestock while maintaining strong market penetration through veterinary channels.

Liver Fluke Treatment Industry News

• In October 2024, Norbrook announced the launch of a diagnostic test for liver fluke. Norbrook in cooperation with The University of Liverpool and Global Access Diagnostics (GADx) have developed this innovative tool to address one of the most common agricultural parasite infections in cattle and sheep. The launch of advanced diagnostic kits helps in early diagnosis of disease, thereby increasing the demand for treatment options.
• In January 2021 Novartis received U.S. Food and Drug Administration (FDA) approval for Egaten (triclabendazole) for the treatment of fascioliasis in patients aged six years and older. This approval marked a significant advancement in the availability of effective treatments for liver fluke infections in the U.S.

The liver fluke treatment market research report includes in-depth coverage of the industry with estimates and forecasts in terms of revenue in USD Million from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Type

• Triclabendazole
• Praziquantel
• Bithionol
• Albendazole
• Nitazoxanide
• Other drug types

Market, By Formulation Type

• Tablets
• Injections
• Oral suspension

Market, By Application

• Human
• Animals

Market, By End Use

• Hospitals
• Clinics
• Veterinary facilities
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina

• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE